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Abstract
Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-
to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs
after experimental stroke under DE treatment as we have shown for warfarin.
Methods: 44 male C57BL/6 mice were pretreated orally with 37.5 mg/kg DE, 75 mg/kg DE or saline and diluted thrombin
time (dTT) and DE plasma concentrations were monitored. Ischemic stroke was induced by transient middle cerebral artery
occlusion (tMCAO) for 1 h or 3 h. We assessed functional outcome and HT blood volume 24 h and 72 h after tMCAO.
Results: After 1 h tMCAO, HT blood volume did not differ significantly between mice pretreated with DE 37.5 mg/kg and
controls (1.560.5 ml vs. 1.860.5 ml, p.0.05). After 3 h tMCAO, DE-anticoagulated mice did also not show an increase in HT,
neither at the dose of 37.5 mg/kg equivalent to anticoagulant treatment in the therapeutic range (1.360.9 ml vs. control
2.360.5 ml, p.0.05) nor at 75 mg/kg, clearly representing supratherapeutic anticoagulation (1.860.8 ml, p.0.05).
Furthermore, no significant increase in HT under continued anticoagulation with DE 75 mg/kg could be found at 72 h
after tMCAO for 1 h (1.760.9 ml vs. control 1.660.4 ml, p.0.05).
Conclusion: Our experimental data suggest that DE does not significantly increase hemorrhagic transformation after
transient focal cerebral ischemia in mice. From a translational viewpoint, this indicates that a continuation of DE
anticoagulation in case of an ischemic stroke might be safe, but clearly, clinical data on this question are warranted.
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Introduction
Atrial fibrillation (AF) is a severe independent risk factor of
stroke, its attributable risk increasing with age up to more than
20% [1]. INR-driven oral anticoagulation with vitamin K
antagonists to an INR of 2–3 reduces the risk of an ischemic
stroke by over 60% [2] and has been the standard of stroke
prevention in patients with AF for over 50 years. In the
Randomized Evaluation of Long-Term Anticoagulation Therapy
(RE-LY) trial, two fixed-dose regimens of dabigatran etexilate (DE)
(110 mg or 150 mg bid) showed a superior risk-to-benefit ratio in
comparison to warfarin in patients with AF for primary and
secondary prevention of stroke [3]. Especially striking was the risk
reduction of intracerebral hemorrhage in both DE dose groups
compared to warfarin. The RE-LY trial establishes DE as an
alternative to warfarin as an anticoagulant for stroke prevention in
patients with AF.
DE is an orally administered prodrug which is rapidly converted
by a serum esterase into its active form dabigatran. As a potent,
competitive and reversible direct thrombin inhibitor, DE reaches
maximum plasma concentrations within 2 hours after oral
administration [4]. It has an estimated half-life time from 12 to
17 hours and 80% are excreted via the kidneys. DE does not
require frequent coagulation monitoring like warfarin and has a
low risk of drug-drug and food-drug interactions. Its predictable
pharmacokinetic profile allows an effective oral anticoagulation
with a fixed-dose regimen [5]. The anticoagulatory effect of DE is
not fully assessed by routine coagulation parameters. While
thrombin clotting time (TT), and activated partial thromboplastin
time (aPTT) are altered by DE, prothrombin time (PT, INR) is not
a useful parameter to evaluate anticoagulant activity of DE [6].
Even under optimal oral anticoagulation, patients with AF still
remain at a residual risk of ischemic stroke. In the RE-LY trial, the
risk of ischemic stroke was 1.34%/yr in the DE 110 mg bid group,
0.92%/yr in the 150 mg DE bid group and 1.2%/yr in the
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e40804warfarin group [3]. Current guidelines do not recommend
anticoagulation in acute cardioembolic stroke and in clinical
practice; warfarin is discontinued in patients with an acute stroke.
We have previously shown that warfarin pretreatment leads to an
excessive hemorrhagic transformation (HT) in mice after tMCAO
[7]. So far, no data on the HT risk after stroke under DE
anticoagulation are available.
The aim of this study was to examine the influence of
dabigatran anticoagulation on hemorrhagic transformation and
neurological outcome in an experimental model of ischemic stroke
in mice.
Methods
Animals
We used male C57BL/6 mice (strain J, 8–10 weeks, mean
25.5 g range 22.7–28.1 g, Janvier, Le Genest Saint Isle, France)
according to the National Institute of Health Guide for the Care
and Use of Laboratory Animals (NIH Publications No. 80–23,
revised 1996). All experiments were approved by the local
governmental authorities (Regierungspraesidium Darmstadt, ap-
proval number F 143/48). All animals received water and food
without restrictions. All surgery was performed under isoflurane
anesthesia and every effort was made to minimize suffering.
ARRIVE guidelines were considered to rise the reproducibility
and quality of our data [8].
Sample Size Calculation and Study Design
Sample size calculation was based upon our previous study
examining HT in vehicle or warfarin-treated mice subjected to the
same stroke model [7]. In this study, an HT volume of 5.262.7 mL
was observed in mice anticoagulated with warfarin to an
international normalized ratio of 2.960.9 prior to 3 h tMCAO
in comparison to an HT volume of 0.360.4 mL in controls who
did not receive a pretreatment. To detect this difference with a
power (1– b) of 0.8 and a level of acceptability of a false positive
result (a) of 0.05, a sample size of 4 animals per group is required.
Anticipating equal or smaller differences in HT between DE and
control animals, we randomized six mice per group. For groups
with an observation period of 72 h after tMCAO, we randomized
seven mice per group to compensate for dead or excluded animals
(Table 1).
First, we ascertained that our DE anticoagulation paradigm
detailed in the following led to DE plasma concentrations that
mirrored the therapeutic situation. In the first experiment, we
randomized six mice per group to DE 37.5 mg/kg or saline to
assess the influence of prior DE anticoagulation on HT volume
and neurological deficit 24 h after the onset of 1 h tMCAO
(Figure 1). Not finding significant differences in this model of
moderate stroke, we randomized six mice per group in the second
part of our study to DE 37.5 mg/kg, DE 75 mg/kg or saline prior
to 3 h tMCAO. In order not to underestimate the risk of HT
under DE anticoagulation, we doubled the DE dose in the second
experiment to mimic the effect of supratherapeutic DE plasma
concentrations that may occur in patients with reduced DE
elimination, i.e. due to renal insufficiency. In the third part of our
study, we randomized seven mice per group to either suprather-
apeutic DE anticoagulation (75 mg/kg) continued over an
observation period of 72 h after 1 h tMCAO or saline. For this
third part of our study, we chose an occlusion time of 1 h, because
mice with an occlusion of 3 h had shown grave weight loss in the
second part of our study as a sign of severe impairment, which
might have led to inacceptably high rates of death and exclusion.
Exclusion Criteria
Exclusion criteria were a missing cerebral blood flow decrease
over the right MCA and/or a missing relevant neurological deficit
(mNSS ,3) as signs of an inadequate MCA occlusion. Massive
bleeding during surgery or death not related to cerebral ischemia
also resulted in exclusion. Therefore, every mouse which died
within 24 h received a complete autopsy for exclusion of
extracranial sources of hemorrhage. Mice with a subarachnoid
hemorrhage (SAH) were also excluded after a complete autopsy. A
weight loss of more than 20% as a sign of severe impairment of the
mice also led to sacrifice and exclusion (Table 1).
tMCAO, Blinding and Randomization
Transient middle cerebral artery occlusion (tMCAO) for 1 or
3 h was performed as described previously [6]. All surgery was
performed in the afternoon under anesthesia with 1.5% isoflurane
(Forene
TM; Abbott, Wiesbaden, Germany) under spontaneous
respiration and 0.1 mg/kg buprenorphine for analgesia (Temge-
sic
TM; Essex Pharma, Munich, Germany). The depth of anesthesia
was tested with the flexor reflex. Focal cerebral ischemia was
induced by inserting standardized monofilaments with a tip
diameter of 0.23 mm into the right MCA, which lead to highly
reproducible ischemic lesion sizes between 5–10% of the
respective mean values [9] (Doccol, Redlands, CA, USA).
Regional cerebral blood flow was constantly monitored by laser
Doppler flowmetry (PF5010, Perimed, Sweden) to confirm vessel
occlusion. Following the operation, all animals received regular
drinking water and food without restrictions. The operator was
blinded to the anticoagulant pretreatment and mice were
randomly assigned to treatment group and sequential order of
operation by a computer generated list [10]. Besides anticoagu-
lation all groups were treated equally. Neurological deficit and
hemoglobin assays were performed in a blinded fashion.
Evaluation of Ischemic Lesion Size
As a pretest for determination of ischemic lesion size after
different tMCAO occlusion times, three groups were evaluated
after 1 h, 2 h or 3 h tMCAO (n=3 per group). We stained freshly
prepared brain slices of 1 mm thickness with 2% 2,3,5-
triphenyltetrazolium chloride (TTC, Merck KgaA, Darmstadt,
Germany) that stains vital mitochondria and performed planim-
etry of the ischemic lesion (white), the contra- and the ipsilesional
hemisphere with the National Institutes of Health Image J
software. Lesion size was corrected for edema by multiplying the
infarct volume by the ratio of the contralateral to the ipsilateral
hemisphere volume.
Oral Anticoagulation with Dabigatran Etexilate
The experimental groups received DE (Pradaxa
TM, Boehringer
Ingelheim, Ingelheim, Germany). 110 mg tablets were freshly
dissolved in 5 ml (22 mg/ml) or 10 ml (11 mg/ml) saline solution.
DE was dosed depending on the target dose (11 mg/ml for
37.5 mg/kg and 22 mg/ml for 75 mg DE/kg) and the body
weight of the mouse. Under a short isoflurane anesthesia 3.4 ml/g
body weight were administered via a gastric tube. Mice were fed
three times with 8 h intervals, the last oral administration was 1
hour before tMCAO or coagulation monitoring, respectively. For
groups with an observation period of 72 h we performed a
maintenance dose every 12 h after surgery. Oral gavages of
comparable dosages were shown to result in significant aPTT
prolongation in rats [11]. Linear dose-dependent aPTT prolon-
gation was also demonstrated by our group in a murine model for
Experimental Stroke under Dabigatran
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volumes of saline solution.
DE concentrations were determined by measuring thrombin
time in diluted samples (dTT) with the Hemoclot
TM test based on
the inhibition of a defined amount of human thrombin (Hyphen
BioMed, Neuville-sur-Oise, France) which enables quantitative
measurement of DTI activity in plasma. 450 or 900 ml mouse
blood was drawn into 0.109 mol/l tri-sodium citrate in a 9:1 ratio
and plasma was obtained by centrifugation (15 min 2500 g at
15uC). Mouse plasma was diluted 1:8 with factor diluent and
mixed with two parts of normal pooled human plasma (50 ml
prediluted mouse plasma and 100 ml normal pooled human
plasma). Clotting was initiated by adding a constant amount of
highly purified human a-thrombin and clotting time was measured
on a calibration curve by using commercially available dabigatran
calibrators. A direct linear relationship between dabigatran
concentrations and clotting time has been shown for TT values
from 30 to 75 seconds [6].
HT Volume Determination
After 24 h, mice were transcardially perfused with 30 ml PBS
under deep isoflurane anesthesia. Hemoglobin concentration was
measured for each hemisphere separately following a previously
described protocol [12]. Hemispheres were homogenized, sub-
jected to ultrasound for 60 s and centrifuged (13.000 rpm, 4uC,
30 min) before photometric analysis of the supernatant mixed with
Drabkin’s Reagent solution (one vial of the Drabkin’s Reagent,
Sigma-Aldrich, Taufkirchen, Germany, with 1000 ml of water
and 0.5 ml of BrijH 35 Solution, Product Code B 4184) in
duplicates at 540 nm. HT volume was calculated based on a
standard curve (data not shown) and the values of both
hemispheres were added for the HT volume of the whole brain.
Mice found dead within the observation period could not be
subjected to transcardial perfusion. In this case, we performed a
total autopsy to exclude extracerebral bleeding and subarachnoid
hemorrhage (SAH) (Table 1). Afterwards, we analyzed the non-
perfused brains and subtracted 0.31 ml from the HT blood
volume. This value was found to be the mean difference in HT
blood volume between 5 unperfused and 5 perfused brains (data
not shown).
Neurological Deficit
Neurological deficit was assessed using the modified Neurolog-
ical Severity Score (mNSS, modified from Chen [13]). The 14-
point-mNSS includes testing hemiparesis, gait, coordination and
sensory functions (Table S1). Pinna and corneal reflex were tested
bilaterally. We assessed mice twice in videotaped sequences just
before reperfusion and at the end of the observation period (Video
S1). Every video sequence includes 60 s spontaneous motion
activity. If mice stopped moving during the observation, they were
stimulated by being raised up a few centimeters. We also
videotaped two attempts of the hanging wire test. We placed the
mice carefully on a bar of wood (8 mm diameter) 20 cm above the
ground until they attained firm grip. The time period to falloff was
recorded with a maximum of 60 seconds. The test was repeated
two times. Mice were not trained before. The observation was
performed by the surgeon in a blinded fashion. Mice that died
within the observation period were given the maximum of 14
points in the mNSS functional outcome score.
Figure 1. Timeline diagram of the experimental procedures.
doi:10.1371/journal.pone.0040804.g001
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Graph Pad Prism 4 (Graph Pad Software Inc., La Jolla, CA,
USA) was used for statistical analysis. Results are given as mean 6
SD and graphically presented as a box and whiskers plot depicting
the median, extreme values and the 25–75 interquartile range.
Statistical significance was assessed with a one-way ANOVA with
Bonferroni’s correction and Bonferroni’s Multiple Comparison
Test for HT values. Gaussian distribution was tested with the
Kolmogorov-Smirnov P value directly, without the Dallall-
Wilkinson-Lilliefor correction, well-knowing that the results for
small sample sizes have to be interpreted very carefully. Neuro-
score data are given as median and range and depicted in a dot
plot. Statistical significance was assessed using a Mann-Whitney
Test for two groups and a Kruskal-Wallis-Test with Dunn’s
correction for three or more groups. For mice that died within the
first 24 h, the maximum mNSS of 14 points was given to perform
an intention-to-treat analysis.
Results
Ischemic Lesion Size
tMCAO for 1 h led to an ischemic lesion size of 44.566.5 mm
3
(n=3) after 24 h, for 2 h tMCAO it was 96.0 mm
3 (n=2, one
mouse died during the operation) and for 3 h tMCAO it was
121.6611.1 mm
3 (n=3) (data not shown).
Anticoagulation Levels
Oral anticoagulation with DE at doses of 37.5 mg/kg and
75 mg/kg led to significant dTT prolongation (37.5 mg/kg:
48.262.8 s vs. 23.260.3 s in control mice; 75 mg/kg:
57.362.8 s;) (Figure 2A). This corresponds to DE plasma
concentrations of 253.3630.6 ng/ml in the group receiving
37.5 mg/kg and 431.1669.8 ng/ml in the group receiving
75 mg/kg while saline-treated controls were at 0 ng/ml
(Figure 2B). Mice with a continuation of anticoagulation over
the observation period of 72 h showed DE plasma concentrations
of 646.0 ng/ml and 767.2 ng/ml, whereas control mice were at
0 ng/ml (data not shown).
DE Anticoagulation does not Lead to Higher HT Volumes
Anticoagulation-naı ¨ve mice showed an HT blood volume of
1.560.5 ml 24 h after 1 h tMCAO. Pretreatment with DE
(37.5 mg/kg) did not lead to a significant increase in HT blood
volume (1.860.5 ml) (Figure 3). In the second part of our study
evaluating HT 24 h after the onset of 3 h tMCAO, pretreatment
with DE 37.5 mg/kg and even DE 75 mg/kg did also not lead to
an increased degree of HT in comparison to non-anticoagulated
mice (2.360.5 ml in control mice vs. 1.360.9 ml in DE 37.5 mg/
kg-treated mice vs. 1.860.8 ml in DE 75 mg/kg-treated
mice)(Figure 3). Even mice with DE anticoagulation that was
continued at supratherapeutic drug levels for 72 h after tMCAO
did not show a significant increase in HT volume compared to
control mice (1.660.4 ml in control mice vs. 1.760.9 mli nD E
75 mg/kg) (Figure 4). All groups passed normality test (p.0.10).
DE Pretreatment has no Influence on Neurological
Outcome after Transient MCAO
In groups with an observation period of 24 h after tMCAO
median mNSS values just before reperfusion after 1 h occlusion of
the right MCA were 11 in non-anticoagulated mice (range 8–12)
and 9 in DE-anticoagulated mice (range 6–12). During the
observation period, both groups showed a functional improvement
without significant differences after 24 h (control: 5, range 3–14 vs.
DE 37,5 mg/kg: 6, range 2–9, p.0.05) (Figure 5).
After 3 h tMCAO, mNSS values directly before reperfusion did
also not show significant differences (control: 12, range 9–13; DE
37.5 mg/kg: 11, range 7–13; DE 75 mg/kg: 12, range 7–13). 24 h
after tMCAO mice showed a slight improvement of their
functional neurological status in all three groups that was more
pronounced in the DE-treated groups (control: 11 range 10–14;
DE 37.5 mg/kg: 8 range 5–10; DE 75 mg/kg: 7 range 7–10)
(Figure 5). Post-hoc power analysis, however, resulted in a
statistical power clearly below 0.8, so a positive of effect of DE
anticoagulation on functional outcome after MCAO cannot be
postulated based on these data.
Mice who were continuously anticoagulated to supratherapeutic
DE levels for 72 h following 1 h tMCAO did also not show a
significant difference in functional neurological outcome com-
pared to the control group (control: median 8.5, range 1–14; DE
Figure 2. DE leads to a prolongation of the dTT in linear
correlation with DE plasma concentrations (Hemoclot
TM as-
say). A) dTT was measured with the Hemoclot
TM assay in anticoagu-
lation-naı ¨ve mice (n=4), mice receiving 3637.5 mg/kg over a 24 h
feeding period (n=3) and mice receiving 3675 mg/kg (n=3). Statistical
significance was assessed with one-way ANOVA and Bonferroni
correction. B) Calibration of the coagulometer with lyophilized standard
DE plasma gives the DE concentration from the dTT values. Statistical
significance was assessed with one-way ANOVA and Bonferroni
correction. ** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0040804.g002
Experimental Stroke under Dabigatran
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the mNSS evaluation after 24 h, the surviving mice showed a
distinct improvement 72 h after surgery. Nevertheless many mice
died before they could reach neurological testing at 72 h, so these
results have to be interpreted very carefully.
Weight loss was not statistically different between treatment
groups after 24 h, neither after 1 h tMCAO nor with 3 h tMCAO
(data not shown). One mouse in the control group (1 h MCAO)
and two mice in the control group (3 h MCAO) died before
evaluation 24 h after tMCAO induction, so they were given a
maximal mNSS score of 14 points.
Mice which died in the two treatment groups with an
observation period of 72 h were also graded 14 on the mNSS.
Both long-term observation groups showed a considerable
mortality within the observation period that was linked to weight
loss and did not differ significantly between DE-treated mice and
controls (Fig. 4).
Discussion
In this study, we investigated whether pretreatment with the
direct thrombin inhibitor DE had an influence on HT volume and
functional outcome in an experimental model of ischemic stroke.
We show that neither HT volume nor functional outcome at 24 h
differ significantly between mice treated with DE or vehicle prior
to 1 h and 3 h tMCAO. The lower dose of our study represents
the therapeutic range measured in participants of clinical trials of
DE taking 150 bid and the higher dose of our study represents
supratherapeutic drug levels. Even mice who were continuously
anticoagulated to supratherapeutic DE levels for 72 hours
following tMCAO did not show an increase of HT compared to
controls. This is in sharp contrast to our previous findings in mice
undergoing MCAO under warfarin anticoagulation [7], which
showed a 14- to 17-fold higher HT blood volume in the brains of
warfarin-anticoagulated mice after tMCAO as compared to
controls in mice anticoagulated to a mean INR of 1.9 and 2.9,
respectively. Our findings indicate a superior safety profile of DE
compared to warfarin in terms of HT after experimental stroke
occurring under anticoagulation. The long-term data with
continued DE anticoagulation over 72 h even show that it might
be safe to continue dabigatran anticoagulation after a stroke under
this treatment.
Figure 3. Mice pretreated with DE did not show a greater risk
of HT after tMCAO than control mice. The left two bars show HT
volume after 1 h MCAO in control mice (n=5) and DE-pre-treated mice
37,5 mg/kg (n=6). Shown on the right is the HT volume after 3 h
MCAO in control mice (n=6), DE-pre-treated mice 37,5 mg/kg (n=5)
and DE-pre-treated mice 75 mg/kg (n=5). Haemoglobin assay was
used for HT blood volume measurement and results are given in ml.
Results are showed in a box and whiskers plot depicting mean values,
extreme values and the 25 to 75 percent interquartile range. Statistical
significance was assessed with a one-way ANOVA with Bonferroni
correction. No significant differences were detected.
doi:10.1371/journal.pone.0040804.g003
Figure 4. No difference in HT and neurological outcome under
continuous anticoagulation 72 h after 1 h tMCAO. A) After 72 h
of continuous anticoagulation after 1 h tMCAO, HT blood volume in DE
75 mg/kg pretreated mice (n=6) and in control mice (n=7) showed no
significant difference. Haemoglobin assay was used for HT blood
volume measurement. Results are given in ml presented in a box and
whiskers plot depicting mean values, extreme values and the 25 to 75
percent interquartile range. B) Neurological function was evaluated on a
14 point scale (mNSS) after 72 h. Mice which died during the
observation period were given 14 points as the worst outcome on
the mNSS scale. The values of single mice and the medians are depicted
in a dot plot. C) The number of surviving mice per group is given
besides their mean body weight in gram.
doi:10.1371/journal.pone.0040804.g004
Experimental Stroke under Dabigatran
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middle cerebral artery occlusion with two different occlusion times
[14]. The infarct sizes in our experimental model for 1 h, 2 h or
3 h occlusion time match infarct sizes obtained in previous
measurements [7]. For the first part of our study we attempted to
model a moderate territorial infarction without malignant brain
swelling, so we chose an occlusion time of 1 h, leading to an
average infarct volume of 44.566.5 mm
3. To exclude the
possibility of an underestimation of the HT risk due to small
lesion sizes with little blood-brain barrier breakdown, we
performed 3 h tMCAO with an average infarct volume of
121.6611.1 mm
3 in the second part of our study, well aware that
such large ischemic lesions, mimicking malignant middle cerebral
artery infarctions, represent only a small fraction of strokes
commonly observed in human patients. However, this experi-
mental paradigm was chosen because it leads to significant
damage at the blood-brain barrier, including activation of matrix
metalloproteinases, disintegration of cell-cell and cell-matrix
junctions and endothelial cell dysfunction [15] and thus represents
maximal ischemic tissue damage rendering the brains most
vulnerable to HT. Several clinical studies, e.g. retrospective
analyses of patient data entered into the National Institute of
Neurological Disorders and Stroke rt-PA trial, identified ischemic
lesion size [16] and stroke severity [17] as independent predictors
of HT risk after stroke.
In previous studies, we established a model for oral anticoag-
ulation with DE in mice [12]. We aimed at carefully controlling
the anticoagulant activity by measuring the DE plasma concen-
tration via the diluted thrombin time (dTT). Oral administration
of DE via gavage for three times during 24 h resulted in stable and
well-reproducible values in the Hemoclot
TM assay. Consistent with
data from humans [6], we have shown previously that prothrom-
bin time (PTT) is less sensitive in detecting DE anticoagulant
effects [12]. There is still a paucity of clinical data on DE plasma
concentrations reached in humans with regular dabigatran intake.
Pharmacokinetic modeling from the PETRO trial and the RE-LY
trial [6,18,19] has shown mean peak plasma concentrations of
184 ng/ml (95% CI 64–443 ng/ml) and trough plasma concen-
trations of 90 ng/ml (95% CI 31–225 ng/ml) in trial patients
administered 150 mg DE bid [6] which is the dose that is currently
used for stroke prevention in atrial fibrillation in patients without a
severe impairment of the renal function. In the RELY-trial, the
vast majority of peak plasma concentrations measured 2 h after
drug intake in both the 110 mg bid and the 150 mg bid regimen
were below 400 ng/ml [18]. Comparing the DE plasma concen-
trations achieved in the two dose groups of our study
(253.3630.6 ng/ml in the group receiving 37.5 mg/kg and
431.1669.8 ng/ml in the group receiving 75 mg/kg) to these
clinical data, the lower of the two dose groups represents average
peak plasma concentrations reached in human trial subjects taking
DE 150 mg bid whereas the higher dose group represents
supratherapeutic DE plasma concentrations which may be
reached in patients at risk for DE accumulation e. g. due to renal
insufficiency. Single DE concentration measurements 72 h after
tMCAO also showed supratherapeutic DE levels of 646.0 and
767.2 ng/ml.
We have previously demonstrated that warfarin pretreatment
withINR values inthetherapeutic rangeused inhumans(INR 2–3)
leadstoaconsiderableincreaseintheriskofHTinasimilarmodelof
large territorial cerebral infarctions [7]. Contrary to those findings,
we did not see any significant increase in HT in mice subjected to
tMCAO under oral anticoagulation with DE, even when DE
anticoagulation to supratherapeutic levels was continued for 72 h.
Fromatranslationalpointofview,thesefindingssuggestthattherisk
HTinpatientssufferingastrokeunderoralanticoagulationwithDE
might be less problematic than in patients anticoagulated with
warfarin and comparable to non-anticoagulated patients and hence
itmightbesafetocontinueoralanticoagulationwithDEafterstroke.
Whereas vitamin K antagonists like warfarin reduce the plasma
concentration of coagulation factors II, VII, IX and X, the direct
thrombin inhibitor dabigatran only targets factor II, resulting in a
less important impact on the coagulation cascade. Previous studies
have shown that deficiencies of the coagulation factors II, VII and
X cause delayed clot initiation and affect clot propagation and clot
strength [20]. Anyhow, a small amount of factor II seems to be
Figure 5. DE pretreatment does not lead to symptomatic
hemorrhagic transformation after tMCAO. A) Neurological
function after 1 h and 3 h tMCAO was assessed on a 14 point scale
(mNSS) directly prior to reperfusion and at B) 24 h. The values of single
mice and the medians are depicted in a dot plot. Statistical significance
was assessed with a Mann-Whitney Test for two groups and a Kruskal-
Wallis-Test with Dunn’s correction for three or more. * p,0.05.
doi:10.1371/journal.pone.0040804.g005
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contrast, almost every decrease of the coagulation factors VII and
X prolongs time to clot [20]. Interestingly, in the RE-LY trial, DE
anticoagulation specifically reduced the risk of intracerebral
hemorrhage compared to warfarin both in the 110 mg bid and
in the 150 mg bid group in patients aged younger and older than
75 years whereas there was a trend towards a higher rate of all
major bleedings in the patients over 75 years receiving DE 150 mg
bid compared to the warfarin group [21]. To date, the mechanism
of this specific protection from intracerebral hemorrhagic compli-
cations under DE treatment compared to warfarin is not clear. It
has been hypothesized that the tissue factor (TF)/factor VIIa
interaction, that provides additional protection in the brain
because the brain shows a high TF expression, is disrupted in
warfarin-treated patients due to the blockage of vitamin K-
dependent c-carboxylation [22]. In DE treated patients, interac-
tion between TF, which is a transmembrane receptor for factor
VIIa, and factor VIIa is not impaired.
Another important characteristic of DE should be mentioned in
this context. The thrombin molecule has three points of interest
for interaction with direct thrombin inhibitors, the active enzyme
site and two exosites, one for fibrin binding and one for heparin
binding [23,24]. Traditional anticoagulants such as unfractionated
heparin and low-molecular-weight heparin need antithrombin as a
cofactor, whereas the univalent thrombin inhibitor DE binds
directly at the active site of thrombin. The exosite 1 is still free for
fibrin polymerization by bridging between fibrinogen molecules
[22]. This might be another reason for the small amount of HT in
our study. Consistently, data from a recent study of our group
showed that DE pretreatment does not lead to hematoma
enlargement in two different models of intracerebral hemorrhage
in mice, whereas the bivalent direct thrombin inhibitor lepirudin
leads to hematoma growth comparable to heparin or warfarin
pretreatment [12].
Some important shortcomings of the present study should be
mentioned. First, even though the coagulation systems of mice and
men are largely similar both in their physiologic properties and in
their reactions in coagulation assays, the differences between the
murine and human coagulation system have not been assessed
with regard to the reaction to DE treatment [25]. Another point of
criticism might be that we only used proximal MCA occlusion
with the filament model leading to territorial infarctions. This type
of infarctions represents one end of the broad spectrum of cerebral
ischemia. In order not to underestimate the influence of DE
pretreatment on spontaneous HT after stroke, we chose moderate
to severe infarctions and a high-dose DE administration reaching
supratherapeutic concentrations. Another issue is the untimely
death of a relevant percentage of our animals. Since we planned
an intention-to-treat analysis, they are included in the analysis but
we tried to make the actual sample sizes of surviving mice very
clear.
In summary, our results suggest that DE, which has been shown
to have a superior risk-to-benefit profile compared to warfarin for
stroke prevention in patients with atrial fibrillation, not only may
lead to considerably less HT if an ischemic stroke occurs under
anticoagulation but might also be safely continued without
interruption after a stroke under anticoagulant treatment. Since
a subgroup analysis of the RE-LY trial identified the CHADS2
score as a suitable predictor of the intracranial bleeding risk for
patients with atrial fibrillation receiving DE [26], the continuation
of DE after a stroke might be especially safe in patients with a low
CHADS2 score. However, direct clinical conclusion from our data
obtained in an experimental stroke model in mice should be
treated with utmost caution and clinical data on these questions
are warranted.
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